Covers a TIM3-targeted nanoformulation that co-delivers venetoclax and NK-engaging antibodies to tackle venetoclax-resistant acute myeloid leukemia and reshape the tumor immune microenvironment.
Key Takeaways
- Although TIM3 represents a promising AML target, clinical blockade has yielded suboptimal outcomes
- We develop VINCENT (VEN-integrated natural killer cell engager targeting TIM3)
- In VEN-resistant AML cell lines and patient-derived xenograft models